JAK2 and cancer: However, a number of studies have shown skewing of the HLA-I and -II genotypes in patients with JAK2 V617F and CALR mutations suggesting those diseases may undergo active immunoediting during their early development (14, 15), which is consistent with the idea that, in many cases, driver cancer mutations are HLA-I and HLA-II restricted (32, 62).